Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen?
Tamoxifen and 4-hydroxytamoxifen protect isolated human low-density lipoproteins (LDLs) against copper-ion-dependent lipid peroxidation: 4-hydroxytamoxifen is more protective than tamoxifen or 17 beta-oestradiol. 4-Hydroxytamoxifen and 17 beta-oestradiol also prevent the increase in the electrophoretic mobility of LDL caused by exposure to copper ions, presumably by protection of the apoprotein B of LDL against oxidative modification. Our observations may help to account for the cardioprotective benefits reported to be associated with tamoxifen therapy and prophylaxis in breast cancer.
Wiseman
H
H
Pharmacology Group, King's College, University of London, U.K.
Paganga
G
G
Rice-Evans
C
C
Halliwell
B
B
D003300:Copper / Q000494:pharmacology*; D004587:Electrophoresis, Agar Gel; D004958:Estradiol / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D015227:Lipid Peroxidation / Q000187:drug effects*; D008077:Lipoproteins, LDL / Q000097:blood* / Q000187:drug effects / Q000302:isolation & purification; D008970:Molecular Weight; D010084:Oxidation-Reduction; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000494:pharmacology*
D008077:Lipoproteins, LDL; D013629:Tamoxifen; C016601:afimoxifene; D004958:Estradiol; D003300:Copper